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Abstract
Background: Many factors have been associated with serum 25-hydroxyvitamin D [25(OH)D] concentrations in
observational studies, with variable consistency. However, less information is available on factors affecting the magnitude
of changes in serum 25(OH)D resulting from vitamin D supplementation.
Objective: This study aimed to identify factors associated with the serum 25(OH)D response to supplementation with
1000 IU cholecalciferol/d during the first year of a large, multicenter, randomized, placebo-controlled colorectal adenoma
chemoprevention trial.
Methods: Eligible older adults who were not vitamin D–deficient [serum 25(OH)D$12 ng/mL] were randomly assigned in
a modified 23 2 factorial design to 1 of 4 groups: daily 1000 IU cholecalciferol, 1200mg Ca as carbonate, both, or placebo.
Women could elect 2-group (calcium6 cholecalciferol) random assignment. In secondary analyses, we usedmultivariable
models to assess factors associated with serum 25(OH)D concentrations in all enrollees (n = 2753) and with relative
changes in serum 25(OH)D after 1 y cholecalciferol supplementation among those randomly assigned (n = 2187).
Results: In multivariable models, 8 factors accounted for 50% of the variability of proportional change in serum 25(OH)D
after cholecalciferol supplementation. Larger increases were associatedwith being female (34.5% comparedwith 20.5%;
P < 0.001) and with lower baseline serum 25(OH)D (P < 0.0001), optimal adherence to study pill intake (P = 0.0002),
wearing long pants and sleeves during sun exposure (P = 0.0002), moderate activity level (P = 0.01), use of extra vitamin
D–containing supplements during the trial (P = 0.03), and seasons of blood draw (P # 0.002). Several genetic
polymorphisms were associated with baseline serum 25(OH)D and/or serum response, but these did not substantially
increase the models R2 values. Other factors, including body mass index, were associated with serum 25(OH)D at
baseline but not with its response to supplemental cholecalciferol.
Conclusions: The factors that most affected changes in serum 25(OH)D concentrations in response to cholecalciferol
supplementation included sex, baseline serum 25(OH)D, supplement intake adherence, skin-covering clothes, physical
activity, and season. Genetic factors did not play a major role. This trial was registered at www.clinicaltrials.gov as
NCT00153816. J Nutr 2016;146:2312–24.
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Introduction
Observational data suggest that inadequate vitamin D status is
associated with an increased risk of fracture, cancer, and other
chronic diseases (1–4). Although the definition of an adequate
serum concentration remains controversial (12 ng/mL) (5, 6), it
has been argued that one-quarter of Americans have inade-
quate serum concentrations of 25-hydroxyvitamin D [25(OH)D]15
(12–20 ng/mL), and 8% are deficient (<12 ng/mL) (7, 8).
However, the National Academy of Medicine (NAM) made
relatively minor changes to DRIs in 2010, stating that
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‘‘a majority of the population is meeting its needs for vita-
min D’’ (7).
Many factors are known to be associated with serum 25(OH)D
concentrations, including sun exposure, BMI, skin pigmentation,
medications, and comorbidities (5, 7–26), but, to our knowledge,
there is limited evidence on a few factors that may affect the
magnitude of serum response to cholecalciferol supplementa-
tion, e.g., baseline serum 25(OH)D, BMI, age, calcium intake,
and season (27, 28). The NAM provides intake recommenda-
tions by age and sex, but it is unclear whether supplementation
should be varied according to vitamin D status, weight, or other
factors (7). In addition, although common genetic variants have
been associated with circulating serum 25(OH)D concentrations
in genome-wide association studies (29, 30), their role in affect-
ing the magnitude of serum response to supplementation is also
less clear (31–33).
In this study, we report the results of analyses of the potential
impact of a large number of personal, medical, environmental,
lifestyle, and genetic factors on the serum 25(OH)D concentra-
tion response to 1 y of oral supplementation with 1000 IU
cholecalciferol/d during a multicenter, randomized, placebo-
controlled colorectal adenoma chemoprevention trial.
Methods
As described previously (34), we conducted a randomized, double-blind,
placebo-controlled trial (NCT00153816) to test the effects of daily
supplementation with 1000 IU cholecalciferol and/or 1200 mg elemental
calcium (as calcium carbonate) on large-bowel adenoma recurrence. From
May 2004 through July 2008, we recruited participants from 11 centers in
the continental United States and Puerto Rico. Participants aged 45–75 y
were eligible for enrollment if they had$1 large-bowel adenoma removed
and no adenomas remaining after a complete colonoscopic surveillance
examination within 4 mo of enrollment. Participants had no familial
colorectal cancer syndromes, no history of serious gastrointestinal disease,
no serious health concerns that might jeopardize several years of partic-
ipation in the trial, and no contraindications to, or medical indications
for, vitamin D or calcium supplementation.
Participants provided detailed information at enrollment on health,
medications, and behavioral factors, such as sun exposure and exercise
[International Physical Activity Questionnaire, Short Form (35)], and
completed the Block Brief 2000 FFQ (Nutritionquest). They were
counseled by study coordinators to help them avoid consuming >1200 mg
Ca and 400 IU vitamin D/d in their food during the study. Participants
also agreed to avoid taking vitamin D or calcium supplements other than
those provided for the trial, but because vitamin D use in the community
gained popularity, the protocol was amended to promote participant
retention. From April 2008 onward, if personal supplements #1000 IU
vitamin D and/or 400 mg elemental calcium were reported as being
taken, these were permitted in addition to the study pills. For those who
wished to take a multivitamin during the study, we provided one that
lacked calcium and vitamin D. Blood drawn at enrollment and 1 y after
random assignment (mean of 14.5 mo after the baseline blood draw)
was tested for 25(OH)D with the use of a Gamma-B 25-Hydroxy
Vitamin D Liquid-Phase RIA kit (IDS) in laboratory processes moni-
tored through the international Vitamin D External Quality Assessment
Scheme. In addition, we genotyped single-nucleotide polymorphisms
(SNPs) in selected genes related to vitamin D metabolism, as described
previously (31): genomic DNAwas isolated from buffy coat samples by
BioServe Biotechnologies with the use of DNAQuiK (36). Genotyping
was conducted by KBioscience with the use of KASP technology (37);
or by Genome Quebec Innovation Center with the use of Sequenom
iPLEX Gold (38) or predesigned TaqMan assays (rs228570 and
rs10766197) (39).
After a placebo run-in phase of 56–84 d, eligible participants who
reported taking $80% of run-in study pills were randomly assigned,
provided that their baseline serum 25(OH)D concentration was $12
ng/mL. Participants were randomly assigned in a modified 23 2 factorial
design stratified by study center, sex, and surveillance interval to 1 of 4
study arms: daily 1000 IU cholecalciferol, 1200 mg Ca as carbonate,
both, or placebo. Women with concerns about osteoporosis who de-
clined to forego calcium supplementation were randomly assigned to
calcium alone or calcium with vitamin D. Tablets for the study were
prepared and tested according to the FDAs guidelines for Good
Manufacturing Practices. Trained study coordinators interviewed ran-
domly assigned participants by telephone biannually to document
changes in health and medications and ascertain self-reported adherence
to study-pill intake. Medications were classified according to their
constituent drug groups (e.g., loop or thiazide diuretic), but for logistical
reasons, drug doses and adherence were not considered in this analysis.
Participation in the trial continued through the next surveillance
colonoscopy after 3 or 5 y, a surveillance interval determined by each
participants medical provider. All candidate variables that were examined
are shown in Supplemental Table 1.
All participants provided written informed consent; the research was
approved by the Committee for the Protection of Human Subjects at
DartmouthCollege and by institutional review boards at each clinical center.
In secondary analyses, we analyzed data from all participants for
whom we had a baseline serum 25(OH)D concentration to identify
factors associated with serum concentrations at enrollment. We identi-
fied potential predictors of serum 25(OH)D concentrations from
published research, and used this information to inform our selection of
variables for analysis. To explore associations of potential exposures
with baseline serum 25(OH)D concentrations, we used linear regression
models. Variables with a univariate P < 0.05 were carried forward to the
multiple linear regression analysis. The general strategy for modeling
included 2 stages: 1) Potential predictors were considered in groups of
similar factors, including demographic, sun-related, behavioral, health,
medication-related, and nutritional. The best model was obtained within
each group by including all variables and then removing the one with the
largest P value > 0.05. The model was then refitted and the process
repeated until all variables remaining had P < 0.05, giving the best
model. 2) All variables from the best group models were entered
simultaneously into a further model, and the same procedure was used to
reduce the variables to a set of variables that were all significant with
P < 0.05, giving the final best model. The 25(OH)D data were positively
skewed and were log transformed for analysis to fulfill the distributional
assumptions.
With the use of the samemodeling strategy, we next examined factors
influencing the serum response to vitamin D supplementation in an
intention-to-treat analysis of randomly assigned participants for whom
we knew both baseline and year 1 serum concentrations. The outcome
variable was the logarithm of year 1 serum 25(OH)D concentration; the
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potential predictors included baseline serum 25(OH)D concentration
and randomly assigned treatment group (vitamin D or placebo). The
rationale for this analysis approach was to adjust the year 1 serum
concentration for baseline serum 25(OH)D concentration and test the
effect of each factor on year 1 serum 25(OH)D concentration while
removing the effect of regression to the mean. Effects of each factor on
response to vitamin D supplementation were tested by fitting the
interaction between that factor and the treatment variable. Estimates
represent the percentage increase in serum 25(OH)D from baseline
associated with supplementation; these are presented separately for
individuals in each category of the variable (e.g., in men and women).
Statistical significance was assessed with likelihood ratio tests. Because
serum 25(OH)D concentration was log transformed, estimated effects
are ratios of geometric means, which are expressed as the percentage
differences in final serum 25(OH)D concentration between those
receiving vitamin D and those receiving placebo. To assist in interpreting
the proportional effects, we also calculated the equivalent changes in
absolute serum 25(OH)D concentration for participants with median
baseline serum 25(OH)D who had increases of 20%, 25%, 30%, 35%,
and 40%. In the final model, we included terms for the main effects of
the stratification factors: study center, colonoscopy surveillance interval,
study arm, and sex.
We conducted exploratory analyses of the effects of medications by
adding each separately to the final model, whether or not it was
significant in univariate analyses. This was done to provide information
systematically on each medication, even though, because of power
issues, most had been excluded from the final model. We also defined
optimal adherence as the self-reported intake of$80% of study pills, on
average, over the entire study period, no personal vitamin D supple-
mentation, and no gaps in pill intake of >7 d. To assess the potential
impact of adherence on these results, we repeated the analyses on the
subgroup of optimally adherent participants.
In a simple exercise, we classified participants at baseline and year 1 into
categories of deficiency (<12 ng/mL), inadequacy (12 to <20 ng/mL), and
adequacy ($20 ng/mL) in order to describe changes in the categories of
vitamin D sufficiency in those treated with vitamin D or placebo (7). We
restricted this analysis to participants who had not been taking vitamin D
supplements at baseline, because only in those participants would the
change in serum 25(OH)D be unaffected by the study requirement to stop
those supplements at enrollment.
Finally, we genotyped 41 SNPs in selected genes involved in the
vitamin D and/or calcium metabolism pathways [selected previously
(31)] to assess their effects on the final model. Population stratification
can lead to spurious associations between genetic markers and disease
phenotypes because of subpopulation heterogeneity in allele frequencies
and disease rates (40); to address this concern, a common statistical
approach is to restrict genetic analyses to a single ethnic or racial group.
We restricted these analyses to our largest subgroup, non-Hispanic
whites, and then developed new multivariable models for baseline
serum 25(OH)D concentrations and for serum response to 1000 IU
cholecalciferol supplementation with the use of the approach described
previously. All 41 SNPs were analyzed univariately with the use of an
additive model. For SNPs that were associated with serum 25(OH)D
baseline concentrations or follow-up changes at P < 0.05, correlations
among them were explored, and for those SNPs in high linkage
disequilibrium, defined as r2 > 0.95, only 1 SNP was included in the
group SNP model. We then added to the final model all SNPs that
remained significant in the group model after backward elimination. For
serum response, we also assessed genetic variant associations within the
optimally adherent subgroup. Analyses were performed with the use of
SAS software version 9.3 and Stata software version 12.
Results
Of 19,083 individuals who were potentially eligible for the trial,
2813 were enrolled, 2753 had baseline serum 25(OH)D mea-
sured, 2259 were randomly assigned, and 2187 were included
in the response analysis (Figure 1). The mean baseline serum
25(OH)D concentration for all 2753 enrollees was (mean 6 SD)
23.9 6 8.6 ng/mL. At enrollment, 54% of participants had been
taking vitamin D supplements and 56% had been taking calcium
supplements; they were asked (and agreed) to stop doing so.
Subsequently, 107 of 2186 (4.9%) reported taking any personal
vitamin D supplements up to 1000 IU/d between random
assignment and year 1. Adequate serum 25(OH)D concentrations
(i.e.,$20 ng/mL) (7) were seen at baseline in 69% of those taking
supplements before enrollment and 54% of those not taking sup-
plements (Table 1).Mean concentrations ranged from24.8 ng/mL in
whites to 18.1 ng/mL in blacks, with the highest concentrations
during the summer and fall, and a downward trend with increasing
BMI (Table 2).
At baseline, the final multivariable model incorporated 17
factors that were significantly associated with serum 25(OH)D
concentration, including demographic, sun-related, health-
related, behavioral, and nutritional factors; those factors
explained 32% of the variability in baseline serum 25(OH)D in
2753 individuals (Table 2). Several medications were associ-
ated with baseline serum 25(OH)D concentrations in univariate
analyses; in multivariable models, current or former users of
hormone replacement therapy had higher serum 25(OH)D
concentrations (P = 0.005), and oral corticosteroid users had
lower concentrations (P = 0.02). When we tested all medications
(even if not significant in univariate analyses) by adding each to
the final adjusted model, calcium channel blockers also were
statistically significantly associated with higher baseline serum
25(OH)D concentrations (P = 0.02) (Supplemental Table 2).
Of 2753 participants included in the baseline analysis, 566
were excluded from the response analysis: 494 failed run-in
[including 97 whose baseline serum 25(OH)Dmeasurement was
<12 ng/mL], and a further 72 randomly assigned participants did
not have a 1-y blood draw (Figure 1). Optimal adherence was
achieved by 1767 (81%). Of the 420 with suboptimal adher-
ence, 228 (10% of the total) reported taking <80% of the pills,
on average; 223 (10%) reported periods of $1 wk without
taking pills; 73 (3%) had taken personal vitamin D supplements
<400 IU/d; 30 (1%) had taken between 400 and 1000 IU/d; 4
had taken large doses (up to 50,000 IU/wk for a limited period);
and 1 failed to report pill intake during the year 1.
After 1 y of supplementation, the unadjusted mean serum
25(OH)D concentration for those randomly assigned to 1000 IU
cholecalciferol/d increased by 6.3 ng/mL, from 24.6 to 30.9 ng/mL.
For those randomly assigned to calcium only or placebo, the
mean serum 25(OH)D concentration fell by 1.1 ng/mL, from
24.5 to 23.4 ng/mL (data not shown), yielding a relative increase
of 7.4 ng/mL, just over 1 SD of baseline concentrations, attribut-
able to cholecalciferol supplementation.
In the multivariable model of serum response to supplemen-
tation, a greater proportional increase in serum 25(OH)D
concentration in the vitamin D group relative to placebo was
associated with lower baseline serum 25(OH)D, being female,
season of each blood draw, wearing long pants and sleeves
during sun exposure, moderate activity level, optimal adherence
to study-pill intake, and use of personal vitamin D–containing
supplements during the trial; these factors explained 50% of the
variability in the serum response in 2157 individuals (R2, Table
3). To illustrate how the model for all participants might be
interpreted, consider an example in which an individual with a
median baseline serum 25(OH)D concentration (23.2 ng/mL)
could expect a 33% (7.6 ng/mL) relative increase after supple-
mentation, to an adjusted year 1 value of 30.8 ng/mL. In post
hoc analysis, we explored the unexpected finding that sex was
associated with serum response to vitamin D supplementation
by adding body weight to the final model. Weight did not
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contribute significantly to the model, nor did it materially alter
the coefficients for sex in the model.
A model developed for the subsample of optimally adherent
participants was similar to the overall model (Supplemental Table
3), except that race was included in the model, whereas physical
activity did not contribute significantly; use of personal vitamin D
supplements could not be included because of the optimal adherence
restriction. Significant univariate SNP analyses in baseline and
response models restricted to non-Hispanic whites are shown in
Supplemental Tables 4 and 5. The serum 25(OH)D concentration
was significantly associated with rs10741657 in cytochrome P450
family 2 subfamily Rmember 1 (CYP2R1; P = 0.0003), and rs4588
in the vitamin D binding protein (GC; P < 0.0001). However,
inclusion of these variables in the final multivariable model barely
changed theR2 from 0.28 to 0.29 and had a substantial impact only
on the coefficients for smoking status (Supplemental Table 4).
When we examined serum response to vitamin D supple-
mentation (Supplemental Table 5), only the rs10766197 poly-
morphism of CYP2R1 contributed significantly (P = 0.001), but,
again, this did not affect the R2 value of 0.48 (Supplemental
Table 5) or the coefficients of the other variables. When we
restricted to optimally adherent participants, 3 polymorphisms
contributed significantly to the final model: rs10766197 in
CYP2R1 (P = 0.01), rs1801725 in the calcium-sensing receptor
(CASR; P = 0.02), and rs4516035 in the vitamin D receptor
(VDR; P = 0.04) (Supplemental Table 6). Inclusion of these
variables in the model marginally increasedR2 from 0.49 to 0.51
(Supplemental Table 6).
In crude analyses of individuals who had not been taking
vitamin D supplements before the study or during year 1, we also
assessed changes in proportions of individuals in the categories
of inadequate (12 to <20 ng/mL) and adequate ($20 ng/mL)
serum25(OH)Dconcentrations (7) (Figure 2). After 1 y, adequate
concentrations were seen in 89% of participants who had
received 1000 IU cholecalciferol/d and in 54% of controls. In
stratified analyses, 83% of those who began with inadequate
concentrations reached adequacy after 1 y of supplementation
compared with 30% of controls. Among those who began the
study with adequate concentrations, 94% of those randomly
assigned to vitamin D were still adequate at 1 y compared with
72% of controls. These figures were similar in participants with
optimal adherence (data not shown).
Discussion
We modeled the determinants of serum 25(OH)D response to
supplementation with 1000 IU cholecalciferol/d after 1 y of
treatment in a large randomized trial in 2187 men and women
aged 45–75 y, from 11 geographically diverse regions of the
United States. At baseline, 17 factors were independently
associated with baseline serum 25(OH)D concentrations, but
we found that 50% of the variability in an individuals response
to supplementation could be explained by baseline serum
25(OH)D concentration and just a few other factors. A greater
proportional serum response was seen with a lower baseline
serum 25(OH)D concentration, being female, optimal adherence,
FIGURE 1 CONSORT flow diagram. CONSORT, Consolidated Standards of Reporting Trials; 25(OH)D, 25-hydroxyvitamin D.
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TABLE 1 Baseline characteristics of participants1
Enrolled
participants
(n = 2753)
Random assignment of participants (n = 2187)
All participants (n = 2187) Optimally adherent participants (n = 1767)
Randomly assigned to
cholecalciferol (n = 1093)
Randomly assigned
to placebo (n = 1094)
Randomly assigned
to cholecalciferol (n = 875)
Randomly assigned
to placebo (n = 892)
Age, y 58.0 6 6.9 58.2 6 6.9 58.0 6 6.8 58.3 6 6.8 58.1 6 6.8
Male 1705 [62] 699 [64] 692 [63] 589 [67] 580 [65]
Race
White 2248 [82] 923 [84] 922 [84] 751 [86] 761 [85]
Black 276 [10] 89 [8.1] 83 [7.6] 63 [7.2] 57 [6.4]
Asian or Pacific Islander 62 [2.3] 25 [2.3] 27 [2.5] 22 [2.5] 24 [2.7]
Other/unknown/refused 167 [6.1] 56 [5.1] 62 [5.7] 39 [4.5] 50 [5.6]
Hispanic ethnicity 201 [7.3] 71 [6.5] 67 [6.1] 47 [5.4] 55 [6.2]
Latitude of study center2
Northern (43–45) 759 [28] 291 [27] 300 [27] 236 [27] 247 [28]
Middle (35–42) 974 [35] 424 [39] 421 [38] 352 [40] 357 [40]
Southern (,35) 1020 [37] 378 [35] 373 [34] 287 [33] 288 [32]
Smoking status
Never 1435 [52] 575 [53] 589 [54] 457 [52] 467 [52]
Former 1031 [37] 406 [37] 413 [38] 328 [37] 350 [39]
Current 287 [10] 112 [10] 92 [8.4] 90 [10] 75 [8.4]
BMI, kg/m2
,25 598 [22] 266 [24] 241 [22] 208 [24] 200 [22]
25–29.9 1108 [40] 443 [41] 447 [41] 358 [41] 368 [41]
30–34.9 695 [25] 253 [23] 277 [25] 204 [23] 218 [24]
$35 347 [13] 130 [12] 127 [12] 104 [12] 105 [12]
Baseline 25(OH)D, ng/mL
Arithmetic mean 23.9 6 8.6 24.7 6 8.2 24.6 6 8.6 24.8 6 8.1 24.8 6 8.6
Geometric mean 22.4 (22.2, 22.7) 23.4 (23.0, 23.9) 23.3 (22.9, 23.8) 23.6 (23.1, 24.1) 23.5 (23.0, 24.0)
Baseline 25(OH)D3
All 2,753 1093 1094 875 892
Deficient 97 [3.5] — — — —
Inadequate 950 [35] 366 [33] 384 [35] 282 [32] 304 [34]
Adequate 1706 [62] 727 [67] 710 [65] 593 [68] 588 [66]
Taking vitamin D at baseline 1493 620 619 497 502
Deficient 30 [2.0] — — — —
Inadequate 440 [29] 180 [29] 183 [30] 137 [28] 145 [29]
Adequate 1023 [69] 440 [71] 436 [70] 360 [72] 357 [71]
Not taking vitamin D at baseline 1260 473 475 378 390
Deficient 67 [5.3] — — — —
Inadequate 510 [40] 186 [39] 201 [42] 145 [38] 159 [41]
Adequate 683 [54] 287 [61] 274 [58] 233 [62] 231 [59]
Vitamin D intake, IU/d
Dietary 132 6 96 132 6 98 137 6 96 130 6 91 138 6 95
Supplements or multivitamins
None 1260 [46] 473 [43] 475 [43] 378 [43] 390 [44]
1–399 66 [2.4] 26 [2.4] 29 [2.7] 17 [1.9] 21 [2.4]
$400 1289 [47] 544 [50] 532 [49] 440 [50] 440 [49]
Unknown amount 138 [5.0] 50 [4.6] 58 [5.3] 40 [4.6] 41 [4.6]
Calcium allocation
No calcium
Run-in failure (not randomly assigned) 494 [18] — — — —
Randomly assigned to take no calcium 835 [30] 409 [37] 405 [37] 339 [39] 332 [37]
Calcium (1200 mg/d)
Randomly assigned to take calcium 840 [31] 410 [38] 403 [37] 334 [39] 335 [38]
Calcium not randomly assigned4 584 [21] 274 [25] 286 [26] 192 [22] 225 [25]
1 Values are means6 SDs, means (95% CIs), or n [%], unless otherwise indicated. When numbers do not sum to column totals, this is due to missing data. 25(OH)D, 25-hydroxyvitamin D.
2 Because California is long and the study center was based in Los Angeles, we used the latitude for Los Angeles (34.1) (41). Northern centers (43–45) included New Hampshire and
Minnesota; middle centers (35–42) included Ohio, Colorado, Iowa, and North Carolina; and Southern centers (18–34) included Puerto Rico, Texas, Georgia, South Carolina, and California.
3 Deficiency (,12 ng/mL) was an exclusion criterion. Inadequate 25(OH)D was defined as 12 to ,20 ng/mL; adequate was defined as $20 ng/mL (7).
4 In the 2-arm randomization protocol, all women received 1200 mg Ca and were randomly assigned to either 1000 IU cholecalciferol/d or placebo.
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TABLE 2 Factors associated with serum 25(OH)D at baseline in older adults who were not vitamin D–deficient who received daily
supplements containing cholecalciferol, calcium, both, or placebo1
n
Baseline serum
25(OH)D,2 ng/mL
Univariate model
Final multivariable
model—R 2 = 0.32 (n = 2465)
Estimate3 P Estimate3 P
Demographic factors
Sex 0.001 ,0.0001
M 1705 24.2 6 8.5 Reference Reference
F 1048 23.3 6 8.7 24.5 (27.1, 21.9) 27.8 (210.8, 24.8)
Race ,0.0001 ,0.0001
White 2248 24.8 6 8.6 Reference Reference
Black 276 18.1 6 6.8 226.9 (230.0, 223.8) 218.4 (222.0, 214.7)
Asian or Pacific Islander 62 19.9 6 6.0 218.7 (225.3, 211.4) 219.1 (225.5, 212.2)
Other/unknown/refused 167 22.4 6 7.3 29.0 (213.7, 24.0) 25.8 (210.6, 20.8)
Year of blood draw ,0.0001 ,0.0001
2004 237 26.0 6 8.7 Reference Reference
2005 704 25.9 6 8.9 20.9 (25.8, 4.4) 6.0 (1.1, 11.1)
2006 836 22.7 6 7.9 212.8 (217.0, 28.3) 25.3 (29.6, 20.8)
2007 688 22.7 6 8.6 213.5 (217.8, 28.9) 25.0 (29.4, 20.3)
2008 288 23.4 6 8.5 210.6 (215.8, 25.1) 3.2 (22.6, 9.3)
Sun-related factors
Season of blood draw ,0.0001 ,0.0001
December–February 624 22.5 6 8.1 Reference Reference
March–May 690 21.7 6 8.0 23.7 (27.2, 0.0) 24.6 (27.7, 21.4)
June–August 758 25.8 6 8.7 15.4 (11.2, 19.6) 14.8 (11.0, 18.6)
September–November 681 25.3 6 8.8 12.8 (8.7, 17.1) 11.4 (7.7, 15.3)
Latitude of study center ,0.0001 ,0.0001
Northern (43–45) 759 23.5 6 8.6 Reference Reference
Middle (35–42) 974 25.0 6 8.8 6.5 (3.0, 10.2) 7.0 (3.8, 10.2)
Southern (,35) 1020 23.1 6 8.3 21.4 (24.6, 1.9) 8.1 (4.7, 11.6)
Artificial tanning ,0.0001 ,0.0001
No 2664 23.6 6 8.4 Reference Reference
Yes 83 32.8 6 10.4 40.1 (29.8, 51.2) 29.1 (20.7, 38.1)
Sunscreen use ,0.0001 0.03
Never or rarely (0–10%) 1486 22.8 6 8.5 Reference Reference
Sometimes (11–85%) 1044 25.1 6 8.5 10.7 (7.7, 13.8) 3.0 (0.4, 5.7)
Almost always (86–100%) 217 25.4 6 9.1 11.3 (5.9, 17.0) 4.4 (20.3, 9.3)
Wears pants and long sleeves in 3-mo
period when outside most
,0.0001 ,0.0001
Never or rarely (0–10%) 1378 25.3 6 8.9 Reference Reference
Sometimes (11–50%) 497 24.0 6 8.4 25.0 (28.3, 21.5) 24.3 (27.3, 21.2)
Usually (51–85%) 269 22.4 6 8.0 211.3 (215.2, 27.2) 27.2 (211.0, 23.3)
Almost always (86–100%) 602 21.1 6 7.6 216.5 (219.2, 213.6) 213.1 (215.7, 210.4)
Vacation days in warm climate, n ,0.0001
None 1221 22.9 6 8.3 Reference —
1–7 670 24.3 6 8.8 6.4 (3.0, 10.0) —
8–14 430 25.0 6 8.8 9.8 (5.7, 14.1) —
15–120 430 24.9 6 8.6 9.1 (5.0, 13.4) —
Behavioral factors
BMI, kg/m2 ,0.0001 ,0.0001
,25 598 26.0 6 9.1 Reference Reference
25–29 1108 24.3 6 8.4 26.0 (29.2, 22.7) 26.9 (29.7, 23.9)
30–34 695 23.4 6 8.4 210.0 (213.4, 26.6) 29.9 (212.9, 26.7)
$35 347 19.9 6 7.1 223.2 (226.6, 219.6) 219.8 (223.0, 216.3)
Smoking status 0.0003 0.002
Never 1435 23.8 6 8.4 Reference Reference
Former 1031 24.4 6 8.8 2.6 (20.2, 5.6) 1.7 (20.9, 4.3)
Current 287 22.5 6 8.9 26.5 (210.6, 22.3) 25.8 (29.5, 21.9)
(Continued)
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TABLE 2 Continued
n
Baseline serum
25(OH)D,2 ng/mL
Univariate model
Final multivariable
model—R 2 = 0.32 (n = 2465)
Estimate3 P Estimate3 P
Alcohol intake, g/d ,0.0001 0.01
#1 875 22.4 6 7.9 Reference Reference
1.1–13.5 903 24.5 6 8.6 9.2 (5.8, 12.8) 2.9 (0.0, 5.8)
13.6–30 414 25.2 6 8.7 12.6 (8.1,17.2) 3.3 (20.4, 7.1)
.30 326 25.9 6 9.5 14.9 (10.0, 20.1) 6.9 (2.7, 11.2)
Activity level4 ,0.0001 ,0.0001
Low 657 22.4 6 8.2 Reference Reference
Moderate 872 23.4 6 8.2 4.2 (0.6, 8.0) 1.6 (21.6, 4.8)
High 1185 25.0 6 8.9 11.3 (7.7, 15.1) 6.4 (3.2, 9.6)
Health-related factors
Ever had hypertension ,0.0001
No 1696 24.4 6 8.8 Reference —
Yes 1056 23.0 6 8.3 25.5 (28.1, 23.0) —
Ever had high cholesterol 0.04
No 1415 24.3 6 8.9 Reference —
Yes 1331 23.5 6 8.2 22.7 (25.2, 20.1) —
Diabetes ,0.0001
No history 2471 24.2 6 8.7 Reference —
Diet controlled 60 22.6 6 8.0 26.7 (214.7, 2.1) —
Not insulin dependent 182 21.1 6 7.2 212.5 (217.0, 27.7) —
Insulin dependent 37 19.5 6 6.2 218.7 (227.5, 28.9) —
Hormone replacement therapy 0.001 0.005
Never 548 22.6 6 8.3 Reference Reference
Former 338 23.6 6 8.7 4.3 (20.8, 9.6) 0.8 (23.3, 5.2)
Current 148 26.0 6 10.1 13.8 (6.5, 21.6) 9.8 (3.7, 16.2)
Taking oral corticosteroid 0.002 0.02
No 2718 23.9 6 8.6 Reference Reference
Yes 35 19.5 6 5.8 216.8 (226.0, 26.4) 211.6 (220.3, 22.1)
Taking any diuretic ,0.0001
No 2243 24.2 6 8.7 Reference —
Yes 510 22.3 6 8.0 27.8 (210.9, 24.6) —
Taking protein pump inhibitor 0.001
No 2375 24.1 6 8.7 Reference —
Yes 378 22.7 6 8.2 26.1 (29.7, 22.5) —
Nutritional factors5
Vitamin D intake via personal supplements, IU/d ,0.0001 0.04
None 1260 23.3 6 8.2 Reference Reference
1–399 66 25.8 6 8.5 17.4 (7.8, 28.0) 13.3 (2.2, 25.5)
$400 1289 25.2 6 8.6 14.1 (11.1, 17.3) 10.3 (2.4, 18.8)
Unknown amount 138 25.4 6 9.6 13.5 (6.8, 20.7) 12.6 (2.8, 23.5)
Calcium intake via personal supplements, mg/d ,0.0001 ,0.0001
None 1211 22.3 6 8.3 Reference Reference
1–200 774 24.7 6 8.5 11.5 (8.1, 15.1) 23.4 (210.6, 4.3)
.200 582 25.9 6 8.8 17.3 (13.4, 21.4) 6.6 (21.3, 15.1)
Unknown amount 186 24.5 6 8.8 10.4 (4.7, 16.5) 21.3 (29.3, 7.4)
Dairy servings6 ,0.0001 ,0.0001
Quartile 1 629 22.2 6 8.1 Reference Reference
Quartile 2 636 23.6 6 8.7 5.7 (1.8, 9.8) 2.6 (20.7, 6.0)
Quartile 3 613 24.2 6 8.3 9.5 (5.4, 13.7) 4.8 (1.4, 8.4)
Quartile 4 641 26.3 6 8.7 19.4 (15.0, 24.0) 12.6 (8.8, 16.5)
Dietary vitamin D intake7 ,0.0001
Quartile 1 626 23.3 6 9.1 Reference —
Quartile 2 634 23.6 6 8.4 2.2 (21.6, 6.2) —
Quartile 3 631 23.7 6 8.2 3.1 (20.8, 7.1) —
Quartile 4 628 25.7 6 8.6 12.4 (8.1, 16.8) —
(Continued)
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season of baseline and year 1 blood draws, wearing pants and
sleeves when out in the sun, physical activity, and personal
vitamin D supplement intake beyond that prescribed. The
rs10766197 polymorphism of CYP2R1 was significantly asso-
ciated with serum response in non-Hispanic whites, but it did
not improve the explanatory value (R2) of the multivariable
model. Although our model confirmed the findings of others that
response to supplementation varies with season of blood
collection and baseline serum 25(OH)D concentration (27, 42),
other aspects of the analysis were unexpected. For example, we
found a significantly greater proportional serum 25(OH)D
concentration increase from supplementation in women than
in men, a finding that, to our knowledge, has not been reported
in other trials (5, 21, 27, 43, 44). We may have seen this result
because our sample size was very large and we could adjust for
many potential confounders. Our results also contrast with
studies that reported a significant association between response
to supplementation and BMI (27), including a systematic review
suggesting that the dose per kilogram of body weight explains
34.5% of the serum response (28). Although BMI affected
baseline serum 25(OH)D concentrations, it did not indepen-
dently affect the serum response to supplementation in our
study. Other studies provide mixed or limited evidence that
response to supplementation is associated with calcium intake,
estrogen use, and dietary fat (27), but our results supported none
of these associations. The inconsistencies seen across studies
may reflect small sample sizes, as well as differences in the
covariates collected and how they were measured. Age and race
were not associated with response to supplementation in our
study or in several others (21, 27, 45–51). Several variables
(being female, greater physical activity, wearing long pants and
sleeves while outdoors, and personal vitamin D supplement use)
contributed significantly to both baseline and response models;
this suggests either that these factors are independent deter-
minants of both baseline serum 25(OH)D concentration and
response to supplementation, or that they have residual effects in
the response model because they are imperfectly represented by
baseline serum 25(OH)D concentration, e.g., because of mea-
surement error. Similarly, some other predictors in the response
model are correlated—e.g., seasons of baseline and year 1 blood
draws and baseline serum 25(OH)D concentration and physical
activity—yet they contributed independently to the final model.
It is possible that some of the variability between studies in the
predictors of response to supplementation may be due to the
intercorrelation of such variables and the impact of collinearity
in model building.
Overall, our model for baseline concentrations contained 17
factors that explained 32% of the variability in baseline serum
25(OH)D.We confirmed the observations of others that baseline
concentrations reflect a variety of personal characteristics;
nutritional, behavioral and lifestyle factors; and measures of sun
exposure (5, 7–26, 42). Our finding of an association between
glucocorticoid use and lower serum 25(OH)D concentrations
adds to mixed evidence from previous studies. Furthermore, it is
unclear whether there is a biological basis for the association, or
if confounding by comorbid illness accounts for it; the latter
possibility is supported by a small meta-analysis that showed
significantly lower serum 25(OH)D in patients treated with
glucocorticoids than in healthy controls, but not in diseased
controls (52, 53). Our finding that hormone replacement ther-
apy was associated with significantly higher serum 25(OH)D
baseline concentrations is supported by Cheng et al. (54) in
univariate but not multivariable models. Alcohol intake was
independently associated with higher baseline serum 25(OH)D
TABLE 2 Continued
n
Baseline serum
25(OH)D,2 ng/mL
Univariate model
Final multivariable
model—R 2 = 0.32 (n = 2465)
Estimate3 P Estimate3 P
Dietary calcium intake8 ,0.0001
Quartile 1 632 22.6 6 8.4 Reference —
Quartile 2 622 23.9 6 8.7 5.7 (1.8, 9.9) —
Quartile 3 635 23.9 6 8.2 6.2 (2.2, 10.3) —
Quartile 4 630 25.9 6 8.7 15.5 (11.2, 20.0) —
Dietary magnesium intake9 0.01
Quartile 1 630 23.3 6 8.7 Reference —
Quartile 2 630 24.3 6 8.5 4.8 (0.8, 8.9) —
Quartile 3 631 23.9 6 8.2 3.5 (20.4, 7.5) —
Quartile 4 628 24.9 6 9.0 7.1 (3.1, 11.3) —
Multivitamin use ,0.0001
No 1265 22.5 6 8.4 Reference —
Yes 1478 25.1 6 8.6 12.7 (9.8, 15.7) —
1 All variables shown had a univariate association with 25(OH)D after all variables in Supplemental Table 1 were tested. When numbers do not sum to 2573, this is due to missing
data. MET, metabolic task equivalent; 25(OH)D, 25-hydroxyvitamin D.
2 Values are means 6 SDs.
3 Percentage change (95% CI) in serum 25(OH)D concentration from baseline to year 1 relative to controls, adjusted for study center, colonoscopy surveillance follow-up interval
(3 or 5 y), sex, and randomization protocol (2- or 4-group).
4 High activity: $3 d/wk of vigorous activity achieving $1500 MET-min/wk, or 7 d of any combination of activities, achieving $3000 MET-min/wk. Moderate activity: $3 d/wk of
vigorous activity of $20 min/d, or $5 d/wk of moderate activity and/or walking of $30 min/d, or $5 d/wk of any activity achieving $600 MET-min/wk. Low: less than moderate
activity level.
5 Sex-specific quartiles were used in nutrition analyses.
6 Cutoffs for quartiles—men: 0.6, 1.0, and 1.7; women: 0.5, 1.0, and 1.5.
7 Cutoffs for quartiles—men: 67.31, 109.12, and 176.10 IU/d; women: 57.37, 99.80, and 157.35 IU/d.
8 Cutoffs for quartiles—men: 444.6, 612.1, and 840.8 mg/d; women: 397.5, 559.4, and 784.5 mg/d.
9 Cutoffs for quartiles—men: 188.0, 242.6, and 310.7 mg/d; women: 159.8, 206.0, and 266.9 mg/d.
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TABLE 3 Factors associated with serum 25(OH)D response to supplementation with 1000 IU cholecalciferol/d in older adults who
were not vitamin D–deficient1
Randomly assigned
to cholecalciferol
(n = 1093)
Randomly assigned
to placebo
(n = 1094)
Univariate model
Multivariable
model—R 2 = 0.50 (n = 2157)
Estimate,2 % P Estimate,2 % P
Baseline serum 25(OH)D,3 ng/mL ,0.0001 ,0.0001
25th percentile (18.2) 41.0 (37.1, 45.1) 32.6 (23.2, 42.7)
50th percentile (23.2) 34.4 (31.4, 37.4) 27.4 (18.5, 36.9)
75th percentile (30.0) 27.8 (24.3, 31.5) 22.2 (13.5, 31.7)
Optimal adherence4 ,0.0001 0.0002
No 218 [20] 201 [18] 21.4 (15.3, 27.8) 20.0 (11.6, 29.1)
Yes 875 [80] 892 [82] 37.7 (34.3, 41.1) 35.0 (24.3, 46.8)
Demographic factors
Sex ,0.0001 ,0.0001
M 699 [64] 692 [63] 29.5 (25.9, 33.2) 20.5 (11.8, 29.9)
F 394 [36] 402 [37] 42.8 (37.6, 48.3) 34.5 (24.7, 45.1)
Race 0.002
White 923 [84] 922 [84] 32.2 (29.0, 35.4) —
Black 89 [8.1] 83 [7.6] 52.5 (40.7, 65.1) —
Asian or Pacific Islander 25 [2.3] 27 [2.5] 53.9 (33.1, 78.0) —
Other/unknown/refused 56 [5.1] 62 [5.7] 34.1 (21.7, 47.7) —
Sun-related factors
Season of baseline blood draw ,0.0001 0.002
December–February 249 [23] 247 [23] 48.6 (41.9, 55.6) 30.8 (19.8, 42.7)
March–May 257 [24] 281 [26] 24.4 (19.0, 30.0) 15.8 (6.4, 26.0)
June–August 308 [28] 288 [26] 28.2 (22.9, 33.7) 30.6 (19.7, 42.4)
September–November 279 [26] 278 [25] 39.8 (33.8, 46.0) 32.9 (21.9, 44.9)
Season of year 1 blood draw ,0.0001 0.001
December–February 272 [25] 265 [24] 42.1 (36.0, 48.4) 31.1 (20.3, 42.8)
March–May 269 [25] 267 [24] 47.6 (41.3, 54.2) 38.4 (27.0, 50.9)
June–August 276 [25] 274 [25] 24.8 (19.5, 30.4) 23.6 (13.4, 34.8)
September–November 276 [25] 288 [26] 24.8 (19.6, 30.3) 17.1 (7.4, 27.7)
Wears pants and long sleeves in 3-mo
period when outside most
,0.0001 0.0002
Never or rarely (0–10%) 560 [51] 565 [52] 28.4 (24.4, 32.5) 19.7 (11.3, 28.8)
Sometimes (11–50%) 175 [16] 205 [19] 33.0 (26.0, 40.4) 22.0 (12.0, 32.9)
Usually (51–85%) 111 [10] 96 [8.8] 46.0 (35.6, 57.0) 35.4 (22.9, 49.2)
Almost always (86–100%) 245 [22] 227 [21] 45.6 (38.7, 52.8) 32.8 (22.5, 43.9)
Behavioral factors
Alcohol intake, g/d 0.04
#1 319 [32] 342 [33] 41.1 (35.5, 47.0) —
1.1–13.5 371 [37] 394 [38] 30.9 (26.0, 35.9) —
13.6–30 179 [18] 155 [15] 32.6 (25.2, 40.4) —
.30 136 [14] 134 [13] 31.1 (23.0, 39.7) —
Activity level5 0.0001 0.01
Low 267 [25] 247 [23] 40.2 (33.9, 46.9) 27.6 (17.5, 38.4)
Moderate 344 [32] 350 [32] 41.4 (35.9, 47.2) 31.9 (22.1, 42.6)
High 467 [43] 485 [45] 27.1 (22.9, 31.5) 22.6 (13.7, 32.2)
Health-related factors
Taking proton-pump inhibitor 0.02
No 942 [86] 922 [84] 32.7 (29.5, 36.0) —
Yes 151 [14] 171 [16] 43.3 (35.1, 52.0) —
Nutritional factors6
Vitamin D intake via personal supplements
during year 1, IU/d
0.0003 0.03
None 1037 [95] 1042 [95] 35.2 (32.2, 38.4) 36.6 (32.1, 41.4)
1–399 39 [3.6] 34 [3.1] 29.1 (14.1, 46.1) 40.1 (24.2, 58.1)
$400 17 [1.6] 17 [1.6] 26.4 (221.8, 12.1) 7.8 (29.4, 28.2)
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concentrations in our study, whereas the evidence from
other studies is mixed (15, 55–59). Surprisingly, we found
that sunscreen use was associated with slightly higher serum
25(OH)D concentrations; this may be because individuals who
regularly use sunscreen have greater sun exposure, but may use
sunscreen ineffectively (7, 60). In contrast, individuals who
regularly wore long pants and long sleeves outdoors had lower
concentrations of serum 25(OH)D, a finding that may relate to
more effective sun protection, or may reflect confounding by
other factors.
Incorporation of selected genetic variants in the full baseline
and response models extended our previous work in mini-
mally adjusted models (31). Although the association between
rs10766197 and serum response is consistent with our previous
TABLE 3 Continued
Randomly assigned
to cholecalciferol
(n = 1093)
Randomly assigned
to placebo
(n = 1094)
Univariate model
Multivariable
model—R 2 = 0.50 (n = 2157)
Estimate,2 % P Estimate,2 % P
Calcium intake via supplements during
year 1, mg/d
0.046
None 1032 [94] 1041 [95] 35.2 (32.2, 38.4) —
1–200 49 [4.5] 30 [2.7] 23.3 (9.1, 39.4) —
.200 12 [1.1] 22 [2.0] 10.8 (28.3, 34.0) —
Dietary vitamin D intake during year 17 0.04
Quartile 1 282 [26] 264 [24] 36.1 (30.1, 42.3) —
Quartile 2 267 [24] 280 [26] 39.7 (33.5, 46.1) —
Quartile 3 279 [26] 268 [25] 34.4 (28.5, 40.6) —
Quartile 4 265 [24] 281 [26] 27.5 (21.9, 33.4) —
Dietary calcium intake during year 18 0.04
Quartile 1 274 [25] 271 [25] 40.5 (34.3, 47.0) —
Quartile 2 289 [26] 259 [24] 35.3 (29.4, 41.6) —
Quartile 3 267 [24] 280 [26] 33.8 (27.9, 39.9) —
Quartile 4 263 [24] 283 [26] 28.0 (22.4, 33.9) —
1 Values are means (95% CIs) or n [%]. All variables shown had a univariate association with 25(OH)D response after all variables in Supplemental Table 1 were tested. When
numbers do not sum to column totals, this is due to missing data. 25(OH)D, 25-hydroxyvitamin D.
2 Percentage change in serum 25(OH)D concentration from baseline to year 1 relative to controls, adjusted for study center, colonoscopy surveillance follow-up interval (3 or 5 y),
sex, and random assignment group (2- or 4-group).
3 Percentiles of baseline serum 25(OH)D are derived from all participants with measured year 1 serum 25(OH)D. To assist with interpretation, the equivalent year 1 serum 25(OH)D
concentration for participants with a median baseline concentration (23.2 ng/mL) and an increase of 20% would be 27.8 ng/mL. Concentrations for other increases are as follows:
25%, 29.0 ng/mL; 30%, 30.2 ng/mL; 35%, 31.3 ng/mL; and 40%, 32.5 ng/mL.
4 Self-reported intake of $80% of study pills, no personal vitamin D supplementation, and no gaps in pill intake of $7 d.
5 High activity: $3 d/wk of vigorous activity achieving $1500 MET-min/wk, or 7 d of any combination of activities, achieving $3000 MET-min/wk. Moderate activity: $3 d/wk of
vigorous activity of $20 min/d, or $5 d/wk of moderate activity and/or walking of $30 min/d, or $5 d/wk of any activity achieving $600 MET-min/wk. Low: less than moderate
activity level.
6 Sex-specific quartiles are calculated for the whole study population.
7 Cutoffs for quartiles—men: 26.6, 59.65, and 114.15 IU/d; women: 18.05, 42.6, and 101.8 IU/d.
8 Cutoffs for quartiles—men: 251.63, 384.35, and 589.65 mg/d; women: 206.80, 317.50, and 497.90 mg/d.
FIGURE 2 Changes in serum
25-hydroxyvitamin D concentrations
in older adults who received daily
supplements containing cholecalcif-
erol, calcium, both, or placebo. Values
shown are the proportions achieving
deficient, inadequate, or adequate sta-
tus after 1 y in each of 4 baseline
categories: 1) inadequate vitamin
D status randomly assigned to placebo
(n = 194), 2) inadequate vitamin
D status randomly assigned to chole-
calciferol (n = 181), 3) adequate vita-
min D status randomly assigned to
placebo (n = 267), and 4) adequate
vitamin D status randomly assigned to
cholecalciferol (n = 279). Individuals
were excluded from analysis if they
were vitamin D–deficient at baseline,
had been taking vitamin D supple-
ments before enrollment, or took per-
sonal vitamin D supplements during
year 1. All measures are unadjusted.
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results (31), 2 polymorphisms (rs6013897 and rs7968585) that
contributed significantly to the minimally adjusted model did
not do so in the full model. Furthermore, the inclusion of genetic
information in the full model in non-Hispanic whites did not
substantially improve theR2 value of the model (R2 = 48%). The
finding that genetic factors may have only a small impact on
serum response is supported by some research (43), but not all
(42). However, even if the impact of the genetic variants appears
to be relatively small overall, there may be cumulative effects in
individuals with multiple risk alleles (61). In the baseline model,
our findings implicating rs10741657 in CYP2R1 and rs4588
(a missense mutation) in GC are largely consistent with other
reports (30, 42, 43, 61, 62). In optimally adherent participants,
our findings implicating rs4516035 in VDR and rs1801725
(a missense mutation) in CASR appear to be novel and merit
further investigation. Recent evidence also suggests that DNA
methylation in CYP2R1 and cytochrome P450 family 24
subfamily A member 1 (CYP24A1) may be associated with
poorer response to vitamin D supplementation (63); we could
not address this question in our study. Ideally, a more compre-
hensive examination of rare and common variations in the
genome will be necessary to further our understanding.
In a crude analysis of participants who had not been taking
vitamin D supplements before enrollment or during year 1 of the
study, adequate concentrations of serum 25(OH)D ($20 ng/mL)
(7) were found after 1 y in 89% of those randomly assigned to
1000 IU cholecalciferol daily, as well as in 54% of controls. The
NAMs RDA [defined as the intake likely to ‘‘meet or exceed the
needs of about 97.5% of the population’’ (7)] is 600 and 800 IU/d
for those aged #70 and >70 y, respectively. Supplementation
with 1000 IU/d did not meet the NAM target in our partici-
pants, a finding that is consistent with the assertion that the
RDAmay not achieve its target in the general population (64, 65).
However, this finding was not adjusted for potential confound-
ing (e.g., by season), and our population had special charac-
teristics that may affect generalizability, including a history of
colorectal adenoma (but not familial polyposis syndromes), the
exclusion of vitamin D–deficient participants (serum 25(OH)D
concentration <12 ng/mL), a lower prevalence of minorities (18%
compared with 28%), and a higher prevalence of overweight
participants (78% compared with 72%) than in the general
population (66, 67).
Our models account for 32% and 50% of the variability in
baseline serum 25(OH)D and the response to supplementation,
respectively. The unexplained variability may relate to differ-
ences in absorption, metabolism, and genetic factors, which we
could not address in this study. Predictions from our overall
model are consistent with those of others. For example, 1000 IU/d
is expected to increase a baseline serum25(OH)Dof 30 to 38 ng/mL
in Garlands model (68) and to 39 ng/mL in ours, although in our
model, optimal adherence increases the postsupplementation
concentration to 42 ng/mL. This difference is not unexpected,
but illustrates the importance of adherence as a source of error
in dose–response estimation during long-term supplementa-
tion. Perhaps not surprisingly, there is considerable variation
within (5) and between (69) studies in the slope representing
the increase in serum 25(OH)D concentration after vitamin D
supplementation. Relative to other studies (69), we observed
only a modest mean increase in serum 25(OH)D concentration of
6.3 ng/mL after supplementation with 1000 IU cholecalciferol/d,
and a decrease of 1.1 ng/mL in controls. Several study-related
factors may have affected these changes: 1) more than one-half of
participants were taking vitamin D supplements at baseline, and
they agreed to stop doing so; 2) participants were counseled
to avoid excessive vitamin D and calcium intake during the study;
and 3) three-quarters of our participants were overweight or
obese, and so would expect a smaller effect than that seen in other
studies (69).
Strengths of our study include the large sample size, inclusion
of racial and ethnic minorities of both sexes, availability of
detailed personal data, good adherence to pill intake, and
detailed information on lapses in pill intake and use of personal
vitamin D supplements (which occurred in <5% of participants).
We avoided bias that could have resulted from regression to the
mean by examining relative proportional increases in our
models, comparing those receiving supplements or placebo.
Limitations of the study include factors affecting generalizabil-
ity, such as our enrollment of individuals with colorectal polyps
and our counseling of participants to avoid excessive dietary
intake of calcium and vitamin D during the study.
In this large, multicenter chemoprevention trial, we found
that 50% of the variability in serum response to supplementa-
tion with 1000 IU cholecalciferol/d was explained by 8 factors:
baseline serum 25(OH)D concentration, sex, optimal adherence,
season, use of long pants and long sleeves for protection from the
sun, physical activity level, and personal vitamin D supplemen-
tation. In contrast to previous smaller studies, we identified a
significantly higher response to supplementation in women than
in men. Associations were identified with several genetic factors
that merit further investigation.
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